These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 14722035

  • 1. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
    Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K, National Cancer Institute of Canada Clinical Trials Group Study MA.19.
    J Clin Oncol; 2004 Jan 15; 22(2):269-76. PubMed ID: 14722035
    [Abstract] [Full Text] [Related]

  • 2. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
    Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, Seymour LK.
    Breast Cancer Res Treat; 2006 Dec 15; 100(3):263-71. PubMed ID: 16823511
    [Abstract] [Full Text] [Related]

  • 3. N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
    Brandes LJ.
    Hum Exp Toxicol; 2008 Feb 15; 27(2):143-7. PubMed ID: 18480139
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
    Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA.
    J Clin Oncol; 2005 Apr 20; 23(12):2831-9. PubMed ID: 15837997
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S.
    J Clin Oncol; 2004 Oct 01; 22(19):3902-8. PubMed ID: 15459211
    [Abstract] [Full Text] [Related]

  • 11. New developments in chemotherapy of advanced breast cancer.
    Lebwohl DE, Canetta R.
    Ann Oncol; 1999 Oct 01; 10 Suppl 6():139-46. PubMed ID: 10676565
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethamine.HCL, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study.
    Brandes LJ, Bracken SP.
    Breast Cancer Res Treat; 1998 May 01; 49(1):61-8. PubMed ID: 9694612
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
    Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE.
    J Clin Oncol; 2004 Dec 01; 22(23):4683-90. PubMed ID: 15570070
    [Abstract] [Full Text] [Related]

  • 15. The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
    Xu FY, Queen G, Brandes L, Hatch GM.
    Proc West Pharmacol Soc; 2007 Dec 01; 50():61-3. PubMed ID: 18605231
    [Abstract] [Full Text] [Related]

  • 16. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L, Cancer and Leukemia Group B.
    J Clin Oncol; 2003 May 01; 21(9):1819-24. PubMed ID: 12721259
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P.
    J Clin Oncol; 2004 May 01; 22(9):1614-20. PubMed ID: 15117983
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI.
    J Clin Oncol; 2008 Jan 01; 26(1):37-43. PubMed ID: 18025439
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.